Literature DB >> 19196746

Dementia.

Alistair Burns1, Steve Iliffe.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19196746     DOI： 10.1136/bmj.b75

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  54 in total

1.  Exaggerated systemic oxidative-inflammatory-nitrosative stress in chronic mountain sickness is associated with cognitive decline and depression.

Authors:  Damian M Bailey; Julien V Brugniaux; Teresa Filipponi; Christopher J Marley; Benjamin Stacey; Rodrigo Soria; Stefano F Rimoldi; David Cerny; Emrush Rexhaj; Lorenza Pratali; Carlos Salinas Salmòn; Carla Murillo Jáuregui; Mercedes Villena; Jonathan D Smirl; Shigehiko Ogoh; Sylvia Pietri; Urs Scherrer; Claudio Sartori
Journal:  J Physiol       Date:  2018-11-24       Impact factor: 5.182

2.  Including People with Dementia in Research: An Analysis of Australian Ethical and Legal Rules and Recommendations for Reform.

Authors:  Nola M Ries; Katie A Thompson; Michael Lowe
Journal:  J Bioeth Inq       Date:  2017-06-20       Impact factor: 1.352

Review 3.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

4.  Integration of temporal and spatial properties of dynamic connectivity networks for automatic diagnosis of brain disease.

Authors:  Biao Jie; Mingxia Liu; Dinggang Shen
Journal:  Med Image Anal       Date:  2018-04-04       Impact factor: 8.545

Review 5.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

6.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

7.  Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

Authors:  Adam Smith; Brian Giunta; Paula C Bickford; Michael Fountain; Jun Tan; R Douglas Shytle
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

8.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

10.  Duration-dependent regulation of autophagy by isoflurane exposure in aged rats.

Authors:  Zheng-Qian Li; Lun-Xu Li; Na Mo; Yi-Yun Cao; Bolati Kuerban; Yao-Xian Liang; Dong-Sheng Fan; De-Hua Chui; Xiang-Yang Guo
Journal:  Neurosci Bull       Date:  2015-08-08       Impact factor: 5.203
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.